A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT00811135
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab [Avastin] — DRUG15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
- capecitabine [Xeloda] — DRUG1000mg/m2 bid po on days 1-14 of each 3-week cycle
- trastuzumab [Herceptin] — DRUG8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
Study Details
This single arm study will assess the efficacy and safety of Avastin in combination with Herceptin and Xeloda as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancer. Patients will receive 3-weekly treatment cycles of Herceptin (8mg/kg iv on day 1 of first cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles), Xeloda (1000mg/m2 bid po on days 1-14 of each treatment cycle) and Avastin (15mg/kg on day 2 of first treatment cycle,and on day 1 of each subsequent cycle).The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Key Dates
- First listed
- Dec 18, 2008
- Start date
- Dec 31, 2008
- Status verified
- Aug 2016
- Primary completion
- Dec 31, 2015
- Completion
- Dec 31, 2015
Study Design
- Enrollment
- 88 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
Primary Outcome Measure
Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) [ Time Frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years) ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland